Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Optimising Radiation Therapy in Head and Neck Cancers Using Functional Image-Guided Radiotherapy and Novel Biomarkers (INSIGHT-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04242459
Recruitment Status : Recruiting
First Posted : January 27, 2020
Last Update Posted : June 17, 2020
Sponsor:
Information provided by (Responsible Party):
Royal Marsden NHS Foundation Trust

Brief Summary:

This is a non-randomised study to develop personalised treatment approaches in participants with Locally Advanced Head and Neck Cancer (HNC) of the oropharynx and base of skull by integrating the use of MR-guided Adaptive Radiotherapy (MRgRT) and functional image-guided radiotherapy (FIgRT).

The study is made up of two parts:

  1. Feasibility planning study consisting of a total of 13 patients. This will include patients with either Human papilomavirus-associated (HPV-associated) oropharyngeal cancer (OPC), Human papilomavirus-negative (HPV-negative) OPC or Base of Skull HNC.
  2. Single centre prospective interventional phase I/II study (main study) made up of 3 independent arms (on the condition of success of the feasibility stage).

    1. Cohort 1: HPV-associated OPC consisting of 25 participants
    2. Cohort 2: HPV-negative OPC consisting of a minimum of 10 patients and a maximum of 53 participants
    3. Cohort 3: Base of Skull HNC consisting of 25 participants

Condition or disease Intervention/treatment Phase
Head and Neck Cancer Radiation: Adaptive Radiotherapy Phase 1 Phase 2

Detailed Description:

This study is looking at improving radiotherapy treatment for head and neck cancers by:

  1. Repeating the radiotherapy planning scan at weeks 2 and 4 of treatment so that investigators can adapt the radiotherapy to changes to the shape of the cancer and the patient's body. These changes can affect the accuracy and the radiotherapy doses delivered.
  2. Using a MR (magnetic resonance) scans to view and target the cancer with more precision.
  3. Identifying HPV negative oropharyngeal cancer who are non-responders and increasing the radiotherapy dose.

The 3 groups of patients are:

  1. Cancers of the oropharynx (middle of the throat) that test positive for HPV (human papilloma virus). If HPV is present, the cancer responds better to treatment and there is a higher chance of cure. In this group, the investigators aim is to reduce radiotherapy associated long-term side effects by sparing healthy tissue from high doses.
  2. If the oropharyngeal cancers test negative for HPV, they are less likely to respond well to treatment. The investigator's department has shown that investigators can predict which patients will respond to treatment using a special type of MR scan. Investigators will increase the dose of radiotherapy to HPV negative patients who are predicted to be non-responders with the aim of improving the chance of cure.
  3. Cancers that located at the base of the skull are not seen very well on CT scan. By using MR imaging, investigators can visualize the surrounding normal organs and the cancer better, target the cancer with more precision and adapt to changes to the healthy organs and tumour.

Investigators will also test if they can predict response to treatment by checking blood for fragments of the cancer and using a special MRI.

The study will be conducted at the Royal Marsden in Sutton only and will be followed up for 2 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 73 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: The study will commence with a Feasibility Radiotherapy planning CT study consisting of 13 participants, then will recruit to the the main phase I/II interventional study consisting of 3 independent cohorts.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Optimising Radiation Therapy in Head and Neck Cancers Using Functional Image-Guided Radiotherapy and Novel Biomarkers
Actual Study Start Date : October 23, 2019
Estimated Primary Completion Date : May 1, 2024
Estimated Study Completion Date : May 1, 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
No Intervention: Feasibility Study
This is a radiotherapy planning study to evaluate the feasibility to acquire longitudinal MRI scans during radiotherapy (prior to the main study) thus, participants will receive standard-of-care chemoradiation therapy (CRT) as per departmental protocol without any treatment adaptation.
Experimental: HPV associated OPC Participants

Participants will be treated initially with the standard radiotherapy dose of:

  • 65 grays (Gy) in 30 fractions (2.17Gy per fraction) over 6 weeks to the primary and nodal tumour.
  • 54Gy in 30 fractions (1.8Gy per fraction) over 6 weeks to the nodal areas at risk of harbouring microscopic disease

In the 2nd week and 4th week of treatment, the participants will undergo Adaptive Radiotherapy to account for anatomical changes.

Radiation: Adaptive Radiotherapy
Determining the radiotherapy dose delivered to organs at risk (OAR) or to the target volume (dependent on what arm the participant is assigned to) through adaptive radiotherapy volume adaption planning

Experimental: HPV negative OPC Participants - Radiotherapy dose escalation

Participants will be treated initially with the standard radiotherapy dose of:

  • 65Gy in 30 fractions (2.17Gy per fraction) over 6 weeks to the primary and nodal tumour.
  • 54Gy in 30 fractions (1.8Gy per fraction) over 6 weeks to the nodal areas at risk of harbouring microscopic disease

After 10 fractions the participants will be stratified into either "responders" or "non-responders" categories based on Apparent Diffusion Coefficients (ADC) response at week 2 of CRT.

Participants classified as "responders" will complete treatment without any radiotherapy dose changes. Their radiotherapy treatment target volumes will be adapted at weeks 2 and 4 of CRT to account for volume changes to the tumour.

The "non-responders" will undergo an increase in dose per fraction to Clinical Target Volume-1 (CTV-1) primary for fractions 11 to 30.

Radiation: Adaptive Radiotherapy
Determining the radiotherapy dose delivered to organs at risk (OAR) or to the target volume (dependent on what arm the participant is assigned to) through adaptive radiotherapy volume adaption planning

Experimental: Base of Skull HNC Participants

Participants will be treated initially with the standard radiotherapy dose of:

  • 65Gy in 30 fractions (2.17Gy per fraction) over 6 weeks to the primary and nodal tumour.
  • 54Gy in 30 fractions (1.8Gy per fraction) over 6 weeks to the nodal areas at risk of harbouring microscopic disease

Participants will undergo standard treatment with 3 cycles of induction chemotherapy followed by chemo-radiotherapy dose. Their radiotherapy treatment will be adapted at weeks 2 and 4 of CRT to account for volume changes to the tumour.

Radiation: Adaptive Radiotherapy
Determining the radiotherapy dose delivered to organs at risk (OAR) or to the target volume (dependent on what arm the participant is assigned to) through adaptive radiotherapy volume adaption planning




Primary Outcome Measures :
  1. Assess the feasibility of participants undergoing MR scan at baseline, week 2 and week 4 and feasibility of producing an adaptive radiotherapy plan [ Time Frame: Through feasibility study completion, estimated 6 months. ]
    To calculate the proportion of participants who have successfully undergone the planned MRI scan at baseline and weeks 2 and 4 to determine the feasibility of producing an adaptive radiotherapy plan in the feasibility study.

  2. Compare the mean cumulative radiotherapy doses Main Study, Cohort 1: Compare the mean cumulative radiotherapy doses received by the parotid gland in an adaptive plan at weeks 3 and 5 to a non-adaptive plan [ Time Frame: Through main study treatment period, estimated 5 years. ]
    To determine the radiotherapy dose delivered to the parotid gland through adaptive radiotherapy volume adaptation planning compared to a non-adaptive radiotherapy approach in the main study, cohort 1.

  3. Assess the safety of radiotherapy dose escalation by measuring the grades of acute radiation induced toxicities using NCI CTCAE v5.0 scores at 3 months [ Time Frame: Through main study treatment period, estimated 5 years. ]
    To assess the safety of radiotherapy dose escalation by measuring the grades of acute radiation induced toxicities which will be assessed using the NCI CTCAE v5.0 scores at 3 months in the main study, cohort 2.

  4. Determine the Maximum Tolerated Dose (MTD) of the escalated radiotherapy dose as per the dose escalation criteria and stopping rules set out in the protocol [ Time Frame: Through main study treatment period, estimated 5 years. ]
    To determine the MTD of the escalated radiotherapy dose in the main study as per the dose escalation criteria and stopping rules as outlined in the protocol in the main study, cohort 2.

  5. Compare the radiotherapy doses to the parotid glands calculated and recorded at baseline with doses from the adaptive plan at weeks 3 and 5 [ Time Frame: Through main study treatment period, estimated 5 years. ]
    To calculate and record radiotherapy doses to the parotid glands at baseline and compare these to doses from the adaptive plan at weeks 3 and 5 in the main study, cohort 3.


Secondary Outcome Measures :
  1. Calculate the proportion of patients who investigators can successfully produce an adaptive radiotherapy plan at weeks 3 and 5 within 1 week of their rescan to account for anatomical changes. [ Time Frame: Through feasibility study completion, estimated 6 months. ]

    To calculate the proportion of patients who investigators can successfully produce an adaptive radiotherapy plan at weeks 3 and 5 within 1 week of their rescan to account for anatomical changes.

    To calculate whether investigators can create an adaptive radiotherapy plan at weeks 3 and 5.


  2. Calculate participants complete response rate at 3 months which is defined as no clinically visible, palpable or measurable disease on imaging or no residual tumour on neck dissection or directed biopsy [ Time Frame: Through main study treatment period, estimated 5 years. ]
    To calculate the complete response rate of participants at 3 months in the main study, cohorts 1-3. Response rate is defined as no clinically visible, palpable or measurable disease on imaging (PET-CT and/or MRI) or no residual tumour on neck dissection or directed biopsy.

  3. Calculate the progression free survival which is defined as the time from entry into the study until disease progression or death (days) [ Time Frame: Through main study treatment period, estimated 5 years. ]
    To calculate the progression free survival which is defined as the time from entry into the study until disease progression or death in the main study, cohorts 1-3. This will be measured in whole days.

  4. Calculate the disease specific survival which is defined as the time from entry into the study until death from any cause (days) [ Time Frame: Through main study treatment period, estimated 5 years. ]
    Calculate the disease specific survival which is defined as the time from entry into the study until death from any cause in the main study, cohorts 1-3. This will be measured in whole days.

  5. Assess quality of life using the EORTC Quality of Life Questionnaire (QLQ) C30 version 3.0 with the associated Head and Neck module (HN35) [ Time Frame: Through main study treatment period, estimated 5 years. ]
    Assess quality of life using the EORTC Quality of Life Questionnaire (QLQ) C30 version 3.0 with the associated Head and Neck module (HN35) in the main study, cohorts 1-3.

  6. Assess late radiation induced toxicities which will be recorded using the late effects in normal tissues subjective, objective, management and analytic scales (LENT SOMA) score and NCI CTCAE v5.0 late radiotherapy scoring systems. [ Time Frame: Through main study treatment period, estimated 5 years. ]
    To assess late radiation induced toxicities which will be recorded using the LENT SOMA score and NCI CTCAE v5.0 late radiotherapy scoring systems. The incidence and prevalence (highest grades) of late side effects of radiotherapy will be reported in the main study, cohorts 1-3.

  7. Calculate the duration of acute radiation induced toxicities will be assessed using the NCI CTCAE v5.0 score (HPV associated OPC and skull base tumours); All participants will be evaluated assess xerostomia, mucositis, dysphagia and dermatitis [ Time Frame: Through main study treatment period, estimated 5 years. ]
    To calculate the duration of acute radiation induced toxicities will be assessed using the NCI CTCAE v5.0 score (HPV associated OPC and skull base tumours); All participants will be evaluated using the NCI CTCAE v5.0 score to assess xerostomia, mucositis, dysphagia and dermatitis in the main study, cohorts 1-3.

  8. Assess the Incidence of feeding tube dependency at one year (HPV negative) which is defined as participant needing supplementation of nutrition by feeding tube. [ Time Frame: Through main study treatment period, estimated 5 years. ]
    To assess the Incidence of feeding tube dependency at one year (HPV negative) which is defined as participant needing supplementation of nutrition by feeding tube In the main study, cohorts 1-3.

  9. Calculate the mean radiotherapy doses to the organs at risk (spinal cord, optic chiasm and brainstem) and target volume will be calculated and recorded at baseline and compared to doses from the adaptive plan at weeks 3 and 5. [ Time Frame: Through main study treatment period, estimated 5 years. ]
    To calculate the mean radiotherapy doses to the organs at risk (spinal cord, optic chiasm and brainstem) and target volume will be calculated and recorded at baseline and compared to doses from the adaptive plan at weeks 3 and 5 in the main study, cohort 3.

  10. Calculate the mean radiotherapy doses to the organs at risk (salivary gland, spinal cord and brainstem) will be calculated and recorded at baseline and compared to doses from the adaptive plan at weeks 3 and 5. [ Time Frame: Through main study treatment period, estimated 5 years. ]
    To calculate the mean radiotherapy doses to the organs at risk (salivary gland, spinal cord and brainstem) will be calculated and recorded at baseline and compared to doses from the adaptive plan at weeks 3 and 5 in the main study, cohort 1.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Feasibility study and Main Study:

  • Participants with stage III/IV ((American Joint Committee (AJC) Tumour, Nodes, Metastasis (TMN) on Cancer Version 7)) head and neck cancer planned for primary radical chemo-radiotherapy OR induction chemotherapy followed by chemoradiotherapy with concomitant platinum-based chemotherapy.
  • Age between 18 and 70 years.
  • Participant can provide informed consent.
  • World Health Organisation (WHO) performance status 0 - 1.
  • Creatinine Clearance >60ml/minute
  • Absolute Neutrophil Count >=1500/mcl
  • Platelets >=100,000/mcl
  • Haemoglobin >=9g/dl

Feasibility Study:

- Participants with either HPV associated OPC, HPV negative OPC or Base of Skull HNC.

HPV associated OPC:

  • Participants with histologically proven squamous cell carcinoma of the head and neck
  • p16 positive (defined as >70% cells staining positive)
  • <10 year pack smoking history

HPV negative OPC

  • Participants with histologically proven squamous cell carcinoma of the head and neck
  • p16 negative
  • >= 4cm in size

Base of skull Head and Neck Cancer:

- Participants with histologically proven squamous cell carcinoma or undifferentiated carcinoma of the head and neck

Exclusion Criteria:

  • WHO performance status >=2.
  • Participants with any previous malignancy except non-melanoma skin cancer.
  • Participants with prior radiotherapy to the head and neck region
  • Participants with contraindications to MRI scan.
  • Participants with contraindications to IV contrast agents.
  • Participants with renal failure

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04242459


Contacts
Layout table for location contacts
Contact: Abi Temple 020 8661 3561 ext 4020 abigail.temple@rmh.nhs.uk
Contact: Amy Scott 020 8661 3561 ext 4020 amy.scott@rmh.nhs.uk

Locations
Layout table for location information
United Kingdom
Head and Neck Unit, Royal Marsden Hospital Recruiting
Sutton, Surrey, United Kingdom, SM2 5PT
Contact: Abi Temple    0208 661 3561 ext 4020    abigail.temple@rmh.nhs.uk   
Contact: Amy Scott    0208 661 3561 ext 4020    amy.scott@rmh.nhs.uk   
Principal Investigator: Shreerang Bhide, MD         
Sub-Investigator: Kevin Harrington, MD         
Sub-Investigator: Christopher Nutting, MD         
Sub-Investigator: Kate Newbold, MD         
Sub-Investigator: Maria Schmidt, MD         
Sub-Investigator: Dow-Mu Koh, MD         
Sub-Investigator: Yong Du, MD         
Sub-Investigator: Derfel Ap Dafydd, MD         
Sub-Investigator: Alex Dunlop, MD         
Sub-Investigator: Dualta McQuaid, MD         
Sub-Investigator: Oliver Gurney-Champion, MD         
Sub-Investigator: Martin Leach, MD         
Sub-Investigator: Sarah Gulliford, MD         
Sub-Investigator: Brian Ng-Cheng-Hin, MD         
Sub-Investigator: Kee Wong, MD         
Sponsors and Collaborators
Royal Marsden NHS Foundation Trust
Investigators
Layout table for investigator information
Principal Investigator: Shreerang Bhide, MD Royal Marsden NHS Foundation Trust
Layout table for additonal information
Responsible Party: Royal Marsden NHS Foundation Trust
ClinicalTrials.gov Identifier: NCT04242459    
Other Study ID Numbers: CCR4934
First Posted: January 27, 2020    Key Record Dates
Last Update Posted: June 17, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Royal Marsden NHS Foundation Trust:
Cancer
Oropharynx
HPV
Base of Skull
Additional relevant MeSH terms:
Layout table for MeSH terms
Head and Neck Neoplasms
Neoplasms by Site
Neoplasms